EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Natural History of Morquio A Syndrome

Shunji Tomatsu iD, Kimberly Klipner iD, Marie Sahou iD, Jacky M Guerrero-Vargas iD, Stuart Mackenzie iD, Lauren Averill iD, Heidi Kecskemethy iD, Yasuhiko Ago iD, Shaukat Khan iD, Chris Church iD, Melissa A Alderfer iD, Thomas H Shaffer iD und 8 weitere

Journal of Inherited Metabolic Disease · 2026-05 · 49 (3)

DOI: 10.1002/jimd.70199 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Inherited Metabolic Disease, online erschienen am 17.05.2026. Verfasst von Shunji Tomatsu und 19 weiteren Autor:innen. Beteiligte Einrichtung: Nemours Children's Health, Wilmington, Delaware, USA. Hauptthemen laut MEDLINE: Mucopolysaccharidosis IV. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 172 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: The Carol Ann Foundation (International Morquio Organization), Eunice Kennedy Shriver National Institute of Child Health and Human Development of the National Institutes of Health (NICHD), Austrian MPS Society.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mucopolysaccharidosis IVA (Morquio A) is a progressive lysosomal disorder caused by a deficiency of N‐acetylgalactosamine‐6‐sulfate sulfatase, resulting in the accumulation of glycosaminoglycans, primarily in cartilage and bone. The condition leads to skeletal dysplasia, impaired ossification, and growth imbalance, causing cervical compression, tracheal obstruction, hip dysplasia, and cardiopulmonary complications. Although existing natural history studies have clarified several aspects of disease progression, objective methods to quantify skeletal pathology and its functional impact remain limited. Standard endurance‐based assessments, including the 6‐min walk test, 3‐min stair climb, and spirometry, are variable and infeasible for young children, wheelchair‐dependent individuals, or patients with respiratory or postoperative limitations. Their dependence on motivation, training, and site‐specific differences restricts their value as reliable endpoints. Significant gaps persist in the objective evaluation of skeletal dysplasia progression and its functional impact. There remains an unmet need for non‐invasive, quantitative tools that capture multisystem involvement across the full phenotypic spectrum. Objective tools exist as we reported but have not been widely implemented or standardized, and data supporting their use as regulatory endpoints remain limited. Emerging longitudinal, multidisciplinary evaluations and surrogate biochemical biomarkers show potential to define disease severity, support prognosis, and serve as validated endpoints for therapeutic monitoring and surgical risk stratification. In conclusion, to address the limitations of prior studies, we propose a novel natural history program of innovative, non‐invasive assessments based on our compiled data. Such approaches may contribute to more consistent longitudinal data and help inform the development of clinical endpoints for emerging therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mucopolysaccharidosis IVHumansDisease ProgressionBiomarkersChondroitinsulfatasesGlycosaminoglycans

Stichwörter der Autor:innen

GALNS deficiencyMorquio A syndromebiomarkersclinical endpointsglycosaminoglycanslysosomal storage disordermucopolysaccharidosis IVAnatural historyskeletal dysplasiatherapeutic development

Substanzen

BiomarkersChondroitinsulfatasesGlycosaminoglycans

Autor:innen und Institutionen

  • Nemours Children's Health, Wilmington, Delaware, USA.

ORCID-Profile: Shunji Tomatsu, Kimberly Klipner, Marie Sahou, Jacky M Guerrero-Vargas, Stuart Mackenzie, Lauren Averill, Heidi Kecskemethy, Yasuhiko Ago, Shaukat Khan, Chris Church, Melissa A Alderfer, Thomas H Shaffer, Tariq Rahman, Abraham Oommen, Claude Beaty, Emi H Caywood, Ayaka Silverman, Takeshi Tsuda, Jobayer Hossain, Lan He

Förderung

  • The Carol Ann Foundation (International Morquio Organization)
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development of the National Institutes of Health (NICHD)
  • Austrian MPS Society
  • NICHD NIH HHS
  • Angelo R. Cali & Mary V. Cali Family Foundation Inc.
  • A Cure for Robert Inc.
  • Nemours Funds
  • The Bennett Foundation

Zitieren

APA

Tomatsu, S., Klipner, K., Sahou, M., Guerrero-Vargas, J. M., Mackenzie, S., Averill, L., Kecskemethy, H., Ago, Y., Khan, S., Church, C., Alderfer, M. A., Shaffer, T. H., Rahman, T., Oommen, A., Beaty, C., Caywood, E. H., Silverman, A., Tsuda, T., Hossain, J., & He, L. (2026). Natural History of Morquio A Syndrome. Journal of Inherited Metabolic Disease, 49(3). https://doi.org/10.1002/jimd.70199

Vancouver

Tomatsu S, Klipner K, Sahou M, Guerrero-Vargas JM, Mackenzie S, Averill L, et al. Natural History of Morquio A Syndrome. Journal of Inherited Metabolic Disease. 2026;49(3). doi:10.1002/jimd.70199

BibTeX
@article{Tomatsu2026,
  author = {Tomatsu, Shunji and Klipner, Kimberly and Sahou, Marie and Guerrero-Vargas, Jacky M and Mackenzie, Stuart and Averill, Lauren and Kecskemethy, Heidi and Ago, Yasuhiko and Khan, Shaukat and Church, Chris and Alderfer, Melissa A and Shaffer, Thomas H and Rahman, Tariq and Oommen, Abraham and Beaty, Claude and Caywood, Emi H and Silverman, Ayaka and Tsuda, Takeshi and Hossain, Jobayer and He, Lan},
  title = {Natural History of Morquio A Syndrome},
  journal = {Journal of Inherited Metabolic Disease},
  year = {2026},
  volume = {49},
  number = {3},
  doi = {10.1002/jimd.70199}
}
Kostenlos starten →